Insulet Corporation (PODD) has a MoatMap StockRank of 45/100 based on Quality (73/100), Value (29/100), and Momentum (29/100) factor scores. The current signal is HOLD. Insulet Corporation is a high-quality medical device company with a strong product and secular growth in diabetes management, fitting the 'Durable Quality & Moats' and 'Peter Lynch' lenses. However, its growth is independent of the specified macro inflection points, lacking the asymmetric macro catalyst required for an 'APPROVE' decision.
Insulet Corporation develops, manufactures, and markets the Omnipod Insulin Management System, a proprietary tubeless insulin pump technology for people with diabetes. Its differentiated tubeless patch pump offers significant convenience and ease of use, fostering strong user loyalty and a recurring revenue model from consumable pods. Insulet is a pioneer and market leader in tubeless insulin pump technology, expanding market penetration and integrated glucose management solutions.
| Price | $146.01 |
| Market Cap | $10.7B |
| P/E (TTM) | 35.93 |
| P/E (Forward) | 19.08 |
| Price/Book | 7.14 |
| Return on Equity | 23.0% |
| Return on Invested Capital | 15.9% |
| Debt/Equity | 77.84 |
| Gross Margin | 71.0% |
| Operating Margin | 16.0% |
| Revenue Growth | 33.9% |
| Free Cash Flow | $253M |
Insulet Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).